Mirum Pharmaceuticals, Inc. (FRA:08D)

Market Cap	5.34B +121.9%
Revenue (ttm)	402.11M +53.7%
Net Income	-35.30M
EPS	-0.72
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Average Volume	1
Open	87.00
Previous Close	85.50
Day's Range	86.50 - 91.00
52-Week Range	32.40 - 90.50
Beta	n/a
RSI	76.38
Earnings Date	Feb 25, 2026

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2018
• Employees: 355
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 08D

Financial Performance

In 2024, Mirum Pharmaceuticals's revenue was $336.89 million, an increase of 80.76% compared to the previous year's $186.37 million. Losses were -$87.94 million, -46.18% less than in 2023.

Financial numbers in USD